Study points to mosapride’s prokinetic effect in endotoxemic horses

Oral mosapride is getting fresh attention in equine medicine after a new Animals paper found the 5-HT4 agonist attenuated gastrointestinal dysmotility during experimentally induced endotoxemia in horses. The study, published September 26, 2026, used a randomized, blinded, three-period crossover design in seven healthy adult horses and tested three conditions: lipopolysaccharide alone, mosapride alone, and lipopolysaccharide plus mosapride. The central finding was straightforward: mosapride appeared to keep exerting prokinetic effects even when acute inflammatory stress was present. (mdpi.com)

That matters because endotoxemia sits at the center of some of equine practice’s hardest gastrointestinal cases. In horses with colic, intestinal ischemia, inflammation, or postoperative complications, endotoxin-driven systemic inflammation can contribute to fever, depression, hemodynamic instability, coagulation changes, and reduced gut motility. Merck’s veterinary reference notes that minimizing inflammatory responses to endotoxemia is a vital part of colic treatment, underscoring why preserving motility during this phase is clinically attractive. (merckvetmanual.com)

Mosapride itself is not a new molecule in horses. Earlier published work found oral mosapride increased electrical activity in the small intestine and cecum of healthy horses in a dose-dependent fashion, with 1.5 to 2 mg/kg identified as the optimal oral range in that experiment. Separate work after jejunocaecostomy also suggested mosapride could help overcome the postoperative drop in intestinal motility. The new study builds on that background by asking a more practical question: does the drug still work when endotoxemia, one of the major biologic drivers of ileus, is actually present? (pubmed.ncbi.nlm.nih.gov)

Based on the journal record, the answer appears to be yes, at least in this controlled model. The investigators enrolled seven healthy adult horses in a crossover trial with 14-day washout intervals and compared LPS alone, mosapride alone, and LPS plus mosapride. The article’s title and abstract summary indicate that oral mosapride attenuated gastrointestinal dysmotility during acute LPS-induced endotoxemia, supporting the idea that its prokinetic action is not fully blunted by the inflammatory state. (mdpi.com)

There does not yet appear to be broad outside commentary on this specific paper, but the finding fits with a longer arc of equine prokinetic research. Older work with cisapride suggested benefit as a prophylactic measure around endotoxemia, while mosapride has been investigated as a potentially safer serotonergic prokinetic with documented effects on equine intestinal electrical activity. At the same time, the evidence base remains early-stage and fragmented, with most studies relying on experimental models or physiologic endpoints rather than large clinical trials in referral-hospital populations. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For equine veterinarians, the practical appeal is obvious. Postoperative ileus, inflammatory bowel dysfunction, and endotoxemia-associated hypomotility can prolong hospitalization, complicate recovery, and increase risk in already fragile horses. A drug that can be given orally and still promote motility during endotoxemia could become a useful adjunct, especially if future studies show benefits on patient-centered outcomes rather than only motility measures. But this paper should be read as signal generation, not practice-changing proof. The sample size was seven horses, the model was experimental, and the study used healthy adults rather than clinical patients with surgical lesions, reflux, pain, fluid shifts, and concurrent therapies. (mdpi.com)

There’s also a regulatory layer. FDA notes that horses are a major species under the Minor Use and Minor Species framework, and the agency offers pathways such as designation, grants, and conditional approval to encourage development for uncommon equine indications. At the same time, FDA also emphasizes that it is illegal to market unapproved new animal drugs. In other words, even promising pharmacology does not automatically translate into a labeled equine product, and any eventual path to routine use would require development work well beyond an experimental crossover study. (fda.gov)

What to watch: The key next milestone is whether investigators or sponsors pursue prospective clinical trials in horses with naturally occurring colic, postoperative ileus, proximal enteritis, or colitis, and whether those studies measure outcomes clinicians care about: reflux, manure production, enteral feeding tolerance, laminitis, complications, and discharge timing. If those data emerge, mosapride could move from an interesting physiologic tool to a more serious candidate in equine GI protocols. (mdpi.com)